1. Introduction 2. Human gut microbial metabolite tryptamine inducing neurodegeneration causes chromosome and genome instability 3. Mutagenicity and genotoxicity of naturally occurring tryptamines and their principle metabolites 4. Abundant urinary tryptamine as indicator of UTI and nosocomial infections 5. Proteus mirabilis, diseases and tryptamine 6. Microbial tryptophan metabolites in cancer and leishmaniasis 7. The effect of human microbial metabolome on multisensory integration in aging and neurodegenerative diseases 8.

Retinitis Pigmentosa (RP): RP-causative gene mutations, RP-related gene mutations, mosaicism and gut microbiome 9. The tRNA aminoacylation interference in diseases 10. Tryptamine interfere with Cytochrome P450 11. Discovery of ADAS and Caudoviricetes prophage markers in metagenomics of type 2 diabetes and associated medical conditions 12. Tryptamine, ADAS and microbiome in Parkinson's disease 13. Gut microbial ADAS and tryptamine in domestic and agricultural animals 14. Tryptamine, stem cell/progenitor protein biosynthesis and aminoacyl-tRNA biosynthesis 15. Tryptamine metabolite indole-3-acetic acid (IAA) in neurodegenerative diseases and other conditions 16.

FDG-PET: tryptamine-treated mouse model and Alzheimer's disease patients. Conceptual evolution of microbiota tryptamine role in human diseases 17. Epilepsy, tryptamine-induced seizures, malfunction of ion channels, electrolyte abnormalities and antibiotic resistance 18. Conclusions.